IL-33 anticorps

N° du produit ABIN1169172

Cité dans 4+ publications. Cet anticorps anti-IL-33 est un anticorps Monoclonal produit chez le Souris, détectant IL-33 dans WB, ELISA, IHC, IP et Func. Convient pour Humain.

Aperçu rapide pour IL-33 anticorps (ABIN1169172)

Antigène: IL-33 (IL33) (Interleukin 33 (IL33))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp IL-33 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP), Functional Studies (Func)

Clone: IL33305B

Détail du produit anti-IL-33 anticorps

Specificité: Recognizes human IL-33.

Réactivité croisée: Humain

Aucune reactivité croisée: Souris

Réactivité croisée (Details): Does not cross-react with mouse IL-33.

Stérilité: 0.2 μm filtered

Immunogène: Recombinant human IL-33.

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.

Agent conservateur: Without preservative

Stock: 4 °C,-20 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Date de péremption: 12 months

Références pour anticorps anti-IL-33 (ABIN1169172)

Pace, Di Sano, Sciarrino, Scafidi, Ferraro, Chiappara, Siena, Gangemi, Vitulo, Giarratano, Gjomarkaj: "Cigarette smoke alters IL-33 expression and release in airway epithelial cells." dans: Biochimica et biophysica acta, Vol. 1842, Issue 9, pp. 1630-7, (2014) (PubMed).

Palmer, Talabot-Ayer, Lamacchia, Toy, Seemayer, Viatte, Finckh, Smith, Gabay: "Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis." dans: Arthritis and rheumatism, Vol. 60, Issue 3, pp. 738-49, (2009) (PubMed).

Chapuis, Hot, Hansmannel, Kerdraon, Ferreira, Hubans, Maurage, Huot, Bensemain, Laumet, Ayral, Fievet, Hauw, DeKosky, Lemoine, Iwatsubo, Wavrant-Devrièze, Dartigues, Tzourio, Buée, Pasquier, Berr et al.: "Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. ..." dans: Molecular psychiatry, Vol. 14, Issue 11, pp. 1004-16, (2009) (PubMed).

Talabot-Ayer, Lamacchia, Gabay, Palmer: "Interleukin-33 is biologically active independently of caspase-1 cleavage." dans: The Journal of biological chemistry, Vol. 284, Issue 29, pp. 19420-6, (2009) (PubMed).

Détails sur IL-33

Antigène: IL-33 (IL33) (Interleukin 33 (IL33))

Autre désignation: IL-33

Sujet: Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30 kDa human IL33 is converted by CASP1 to a 18 kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.

UniProt: O95760

Pathways: Production of Molecular Mediator of Immune Response